Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare metabolic diseases.
Excellent balance sheet and slightly overvalued.
Share Price & News
How has Amicus Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: AM6 has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: AM6 underperformed the German Biotechs industry which returned 9% over the past year.
Return vs Market: AM6 underperformed the German Market which returned 14.4% over the past year.
Price Volatility Vs. Market
How volatile is Amicus Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Amicus Therapeutics undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: AM6 (€9.85) is trading below our estimate of fair value (€55.65)
Significantly Below Fair Value: AM6 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: AM6 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: AM6 is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AM6's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AM6 is overvalued based on its PB Ratio (5x) compared to the DE Biotechs industry average (3.6x).
How is Amicus Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AM6 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: AM6 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: AM6 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: AM6's revenue (36.7% per year) is forecast to grow faster than the German market (5% per year).
High Growth Revenue: AM6's revenue (36.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AM6 is forecast to be unprofitable in 3 years.
How has Amicus Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AM6 is currently unprofitable.
Growing Profit Margin: AM6 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AM6 is unprofitable, and losses have increased over the past 5 years at a rate of -32.4% per year.
Accelerating Growth: Unable to compare AM6's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AM6 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).
Return on Equity
High ROE: AM6 has a negative Return on Equity (-62.88%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is Amicus Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: AM6's short term assets ($576.7M) exceed its short term liabilities ($93.1M).
Long Term Liabilities: AM6's short term assets ($576.7M) exceed its long term liabilities ($240.9M).
Debt to Equity History and Analysis
Debt Level: AM6's debt to equity ratio (27.2%) is considered satisfactory.
Reducing Debt: AM6's debt to equity ratio has reduced from 32.4% to 27.2% over the past 5 years.
Inventory Level: AM6 has a low level of unsold assets or inventory.
Debt Coverage by Assets: AM6's debt is covered by short term assets (assets are 3.9x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AM6 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if AM6 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Amicus Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate AM6's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate AM6's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AM6's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AM6's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AM6's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
John Crowley (52yo)
Mr. John F. Crowley has been the Chairman of Amicus Therapeutics, Inc. since February 2010 and has been its Chief Executive Officer since August 15, 2011. Mr. Crowley served as the Chief Executive Officer ...
CEO Compensation Analysis
Compensation vs Market: John's total compensation ($USD7.42M) is above average for companies of similar size in the German market ($USD2.18M).
Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.
|Chairman & CEO||8.5yrs||US$7.42m||0.39% $9.9m|
|Chief Legal Officer & Corporate Secretary||4yrs||US$2.08m||0.079% $2.0m|
|Chief Medical Officer||5.9yrs||US$2.09m||0.061% $1.6m|
|Chief Financial Officer||1.1yrs||US$325.40k||0.075% $1.9m|
|Global Controller & Principal Accounting Officer||1.7yrs||no data||0.0024% $62.1k|
|Senior Vice President of Technical Operations||0yrs||no data||no data|
|Chief Scientific Officer||4.6yrs||US$1.27m||0.20% $5.1m|
|Vice President of Investor Relations & Corporate Communications||0yrs||no data||no data|
|Senior VP||4.5yrs||no data||no data|
Experienced Management: AM6's management team is considered experienced (4.5 years average tenure).
|Chairman & CEO||8.5yrs||US$7.42m||0.39% $9.9m|
|Independent Director||7.7yrs||US$199.71k||0.0035% $88.9k|
|Independent Director||0.7yrs||no data||0.0019% $49.4k|
|Independent Director||13.7yrs||US$219.71k||0.0086% $218.2k|
|Independent Director||10.3yrs||US$217.21k||0.0074% $188.9k|
|Independent Director||7.7yrs||US$209.71k||0.059% $1.5m|
|Independent Director||3.7yrs||US$204.71k||0.0035% $88.9k|
|Lead Independent Director||1.4yrs||US$257.27k||0.0035% $88.9k|
|Independent Director||1.4yrs||US$257.49k||no data|
Experienced Board: AM6's board of directors are considered experienced (5.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 24.4%.
Amicus Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Amicus Therapeutics, Inc.
- Ticker: AM6
- Exchange: DB
- Founded: 2002
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$2.754b
- Listing Market Cap: US$2.546b
- Shares outstanding: 254.81m
- Website: https://www.amicusrx.com
Number of Employees
- Amicus Therapeutics, Inc.
- 1 Cedar Brook Drive
- New Jersey
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|FOLD||NasdaqGM (Nasdaq Global Market)||Yes||Common Stock||US||USD||May 2007|
|AM6||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||May 2007|
|0HF9||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||May 2007|
Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare metabolic diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting Phase 1/2 (ATB200-02) and Phase 3 (ATB200-03) clinical studies for an investigational enzyme replacement therapy (AT-GAA) for Pompe disease. The company has a research and development collaboration with the University of Pennsylvania to develop AAV gene therapies; and a strategic manufacturing agreement with Catalent Biologics. The company also has a strategic manufacturing collaboration with Thermo Fisher Scientific for conducting preclinical and clinical-stage gene therapy programs for CLN6, CLN3, and other Batten disease programs. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/19 21:47|
|End of Day Share Price||2020/02/19 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.